Rani Therapeutics HoldingsRANI -0.51%32 PS Ratio is 31.70 as of Jun. 30, 2026, which is 30% below its 10-year median of 45.02. GuruFocus rates RANI with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 935 Biotechnology companies, Rani Therapeutics Holdings ranks worse than 73.26% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Rani Therapeutics Holdings's share price is $0.7608.
Rani Therapeutics Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.02. Hence, Rani Therapeutics Holdings's PS Ratio for today is 31.70.
The historical rank and industry rank for Rani Therapeutics Holdings's PS Ratio or its related term are showing as below:
RANI'
s PS Ratio Range Over the Past 10 Years
Min: 11.54 Med: 45.02 Max: 219.74
Current: 31.69
During the past 7 years, Rani Therapeutics Holdings's highest PS Ratio was 219.74. The lowest was 11.54. And the median was 45.02.
RANI's PS Ratio is ranked worse than 73.26% of 935
companies
in the Biotechnology industry
Industry Median: 9.37
vs RANI: 31.69
During the past 7 years, Rani Therapeutics Holdings's highest 3-Year average Revenue per Share Growth Rate was -36.30% per year. The lowest was -36.30% per year. And the median was -36.30% per year.
Back to Basics: PS Ratio
Rani Therapeutics Holdings (NAS:RANI) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Rani Therapeutics Holdings PS Ratio Related Terms
Rani Therapeutics Holdings PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Rani Therapeutics Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rani Therapeutics Holdings PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rani Therapeutics Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where Rani Therapeutics Holdings's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Rani Therapeutics Holdings's Share Price of today is $0.7608. Rani Therapeutics Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Rani Therapeutics Holdings (RANI) has a PS Ratio of 31.70 as of Jun. 30, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Rani Therapeutics Holdings and its competitors. This is 30% below median its historical median of 45.02. Over the past decade, Rani Therapeutics Holdings' PS Ratio has ranged from 11.54 to 219.74. According to the industry distribution chart, Rani Therapeutics Holdings ranks #685 out of 935 companies in the Biotechnology industry, placing it in the top 73.3%.
Is Rani Therapeutics Holdings' PS Ratio too high?
Rani Therapeutics Holdings' current PS Ratio of 31.70 is 30% below median its 10-year median of 45.02. Over the past 10 years, this metric has ranged from a low of 11.54 to a high of 219.74. The Biotechnology industry median PS Ratio is 9.37. Rani Therapeutics Holdings' value of 31.70 is 238.3% above this industry median. Based on the distribution chart, Rani Therapeutics Holdings ranks #685 out of 935 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Rani Therapeutics Holdings has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Rani Therapeutics Holdings' PS Ratio compare to IBIO and RNTX?
According to the Biotechnology industry distribution chart, Rani Therapeutics Holdings ranks #685 out of 935 companies for PS Ratio. This places Rani Therapeutics Holdings in the lower half of its industry. The industry median PS Ratio is 9.37. Rani Therapeutics Holdings' value of 31.70 is 238.3% above this benchmark. Historically, Rani Therapeutics Holdings' own PS Ratio has ranged from 11.54 to 219.74 over the past decade. While the company's 10-year median is 45.02 vs. the industry median of 9.37, Rani Therapeutics Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.37, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rani Therapeutics Holdings's current PS Ratio of 31.70 is 238.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Rani Therapeutics Holdings and its competitors. For the Biotechnology industry, the median PS Ratio is 9.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rani Therapeutics Holdings's current PS Ratio is 31.70, which is 30% below median its own 10-year median of 45.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rani Therapeutics Holdings stock overvalued right now?
Rani Therapeutics Holdings (RANI) has a current PS Ratio of 31.70. The current PS Ratio is 31.70, which is 30% below median its 10-year median of 45.02 and 238.3% above the Biotechnology industry median of 9.37. Rani Therapeutics Holdings' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Rani Therapeutics Holdings (RANI), the current PS Ratio is 31.70 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
32GF Score
Get the complete analysis for RANI
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RANI has been successfully added to your 
